Pharma's Market

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University

MORE HEADLINES

» Markets | Economy | Companies

- MBS Buyback Program Should be Extended: Fed's Bullard

PHARMA'S MARKET VIDEO

» More

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

Cholesterol Drug Battle: Merck vs. Abbott Labs

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.

Cholesterol Drug Battle 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

All In The Family

Published: Tuesday, 14 Jul 2009 | 11:34 AM ET

Text Size

By: Mike Huckman
Reporter

Mike and his sister.

I was so shocked and surprised when I opened an email this past weekend from my sister in California.

(Before I go any further, she gave me her permission to blog about it.)

She blitzed our extended family to inform us that she was at home recuperating from a gastric bypass.

She's been a yo-yo dieter for nearly all of her adult life, but I never saw her as obese.

A little heavy, overweight, maybe.

But not obese.

When I called her to talk about the news, my sister explained that she had only told her immediate family in advance of the procedure because she didn't want the rest of us offering opinions and advice. I get that. I asked her if she was classified as overweight or obese. She paused and then told me she was embarrassed to answer. She took a breath and said she had peaked at 237 pounds and had a body mass index of 41, one point over the BMI bar she said she needed to hit in order to qualify for the bypass operation. She was obese. I still have a hard time getting my head around that and thinking of her as being in that category. She considered the "Lap Band" from Allergan, but decided, as she put it, that she "didn't want plastic" in her body.

Americans And Their Food

Fast Food As Haute Cuisine Recession Special: Steak for $5!Recession Undercuts Prices on Guilty Pleasures Lobster At Lunch-Meat Prices

I briefly had a weight problem when I was in my early 20s. I'd moved to Montana to start my career and spent many nights out drinking too much Ranier beer. Next thing I knew, I had a paunch. But it wasn't until a few years later when I moved to Tucson that I joined a gym. I dropped the extra pounds in a matter of weeks and they've never come back.

For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister. Arena Pharmaceuticals, Orexigen and Vivus each has a new diet drug in late-stage development. We're going to see a lot of important test results out of all three of them in the near future. And last week, Amylin Pharmaceuticals unveiled promising mid-stage test results of an obesity treatment it's working on.

Battling Obesity

The Centers for Disease Control estimates that 29 percent of the U.S. population is obese. Two-thirds of Americans are overweight or obese. It is a multi-billion-dollar opportunity for companies that can develop something that works safely. If they're successful, though, I hope and pray my sister will no longer need it. I also wish her a speedy recovery, much success with her new lifestyle and, of course, good health.

P.S. Even though people say my sister and I look alike, I was adopted. My sister was not.

Questions? Comments? and follow me on Twitter at mhuckman